VIRxSYS gains $20M in financing

Weeks after it released positive data on an early-stage study of its experimental gene therapy for HIV, VIRxSYS has raised $20 million in a series G round of financing. Some of that money will be used to support a Phase II trial of VRX496 for HIV. VRX496 relies on an HIV-based lentiviral vector--or viral container--from which the disease-causing aspects of the virus have been removed, leaving behind an efficient gene-delivery vehicle. VIRxSYS then equips the vector with a long antisense sequence against the HIV envelope protein to create VRX496.

- check out the release on the new round

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.